inTRAvent Medical

Executive Summary

inTRAvent Medical Partners is a privately held medical device company headquartered in Hershey, PA, dedicated to improving neurosurgical precision at the bedside. Its flagship product, the SOLOPASS® system, is FDA-cleared and designed to enhance the accuracy of external ventricular drain (EVD) placement, a common but high-risk procedure in intensive care. By bringing intra-operative imaging and navigation capabilities directly to the patient's bedside, the company aims to reduce procedural variability and improve patient outcomes. Founded in 2015, inTRAvent addresses a critical unmet need in neurocritical care, where misplaced EVDs can lead to serious complications. The company's technology has the potential to become the standard of care for bedside ventriculostomy, offering a portable and cost-effective alternative to traditional navigation systems that are limited to operating rooms. The market opportunity is substantial, with hundreds of thousands of EVD placements performed annually in the U.S. alone. inTRAvent's SOLOPASS system differentiates itself through its simplicity, accuracy, and integration into existing clinical workflows. However, as a small private company, it faces challenges in commercial scaling and competing against established players. The company's future growth hinges on successful market adoption, potential expansion of its product pipeline, and strategic partnerships. With increasing emphasis on reducing healthcare costs and improving procedural safety, inTRAvent is well-positioned to capture a significant share of the neurosurgical navigation market, provided it can execute on its commercialization strategy and secure additional funding or partnerships to accelerate adoption.

Upcoming Catalysts (preview)

• Q4 2026Expansion of SOLOPASS into new hospital systems or international markets60% success
• Q2 2027FDA clearance for next-generation device or additional indications50% success
• TBDStrategic partnership or acquisition by a larger medtech company30% success